Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Gulley Website

James L. Gulley, M.D., Ph.D.

Selected Publications

1)  Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW, Feldman J, Poole DJ, Litzinger M, Steinberg SM, Jones E, Chen C, Marte J, Parnes H, Wright J, Dahut W, Schlom J, Gulley JL.
Clinical safety of a viral vector based prostate cancer vaccine strategy.
J. Urol. 178: 1515-20, 2007.
[Journal]
2)  Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR.
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
J. Clin. Oncol. 28: 1099-105, 2010.
[Journal]
3)  Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, Jones JL, Poole DJ, Higgins JP, Hodge JW, Cereda V, Vergati M, Steinberg SM, Halabi S, Jones E, Chen C, Parnes H, Wright JJ, Dahut WL, Schlom J.
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
Cancer Immunol. Immunother. 59: 663-74, 2010.
[Journal]
4)  Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, Dahut WL, Schlom J, Gulley JL.
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
Lancet Oncol. 13: 501-8, 2012.
[Journal]
5)  Gulley JL, Heery CR, Madan RA, Walter BA, Merino MJ, Dahut WL, Tsang KY, Schlom J, Pinto PA.
Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.
Cancer Immunol. Immunother. 62: 1521-31, 2013.
[Journal]
6)  Jochems C, Tucker JA, Tsang KY, Madan RA, Dahut WL, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J.
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.
Cancer Immunol. Immunother. 63: 407-18, 2014.
[Journal]
7)  Campbell CT, Gulley JL, Oyelaran O, Hodge JW, Schlom J, Gildersleeve JC.
Humoral response to a viral glycan correlates with survival on PROSTVAC-VF.
Proc. Natl. Acad. Sci. U.S.A. [Epub ahead of print], 2014.
[Journal]
8)  Jochems C, Tucker JA, Vergati M, Boyerinas B, Gulley JL, Schlom J, Tsang K.
Identification and characterization of agonist epitopes of the MUC1-C oncoprotein.
Cancer Immunol. Immunother. 63: 161-74, 2014.
[Journal]
9)  Farsaci B, Jochems C, Grenga I, Donahue RN, Tucker JA, Pinto PA, Merino MJ, Heery CR, Madan RA, Gulley JL, Schlom J.
Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets.
Int. J. Cancer. [Epub ahead of print], 2014.
[Journal]
10)  Gulley JL, Madan RA, Tsang KY, Jochems C, Marté JL, Farsaci B, Tucker JA, Hodge JW, Liewehr DJ, Steinberg SM, Heery CR, Schlom J.
Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.
Cancer Immunol Res. 2: 133-41, 2014.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 6/18/2014.